Brianne, Alzheimers, Probiotics, and CBD

Monday, 14 January 2019

“In a remarkable paper, neurologist Ethan Russo connects receptors, epidemiology, the microbiome, neuroinflammation, and cannabis to explain possible therapeutic targets in treatments of troubling neurodegenerative conditions like Parkinson’s and Alzheimer’ Diseases. I challenge you to follow the bouncing ball. This one paper could keep the entireIvy League busy for a decade.”
- Dr. David Hepburn


Neurological therapeutics have been hampered by its inability to advance beyond symptomatic treatment of neurodegenerative disorders into the realm of actual palliation, arrest or reversal of the attendant pathological processes.

While cannabis-based medicines have demonstrated safety, efficacy and consistency sufficient for regulatory approval in spasticity in multiple sclerosis (MS), and in Dravet and Lennox-Gastaut Syndromes (LGS), many therapeutic challenges remain. 

The review examines the intriguing promise that recent discoveries regarding cannabis-based medicines offer to neurological therapeutics by incorporating the neutral phytocannabinoids tetrahydrocannabinol (THC), cannabidiol (CBD), their acidic precursors, tetrahydro cannabinolic acid (THCA) and cannabidiolic acid (CBDA), and cannabis terpenoids in the putative treatment of five syndromes, currently labeled recalcitrant to therapeutic success, and wherein improved pharmacological intervention is required: intractable epilepsy, brain tumors, Parkinson disease (PD), Alzheimer disease (AD) and traumatic brain injury (TBI)/chronic traumatic encephalopathy (CTE).

Read the full article here:

Dr. Dave Hepburn website:


Post a Comment

Related Posts Plugin for WordPress, Blogger...